iScience (Feb 2024)

Cancer selective cell death induction by a bivalent CK2 inhibitor targeting the ATP site and the allosteric αD pocket

  • Alexandre Bancet,
  • Rita Frem,
  • Florian Jeanneret,
  • Angélique Mularoni,
  • Pauline Bazelle,
  • Caroline Roelants,
  • Jean-Guy Delcros,
  • Jean-François Guichou,
  • Catherine Pillet,
  • Isabelle Coste,
  • Toufic Renno,
  • Christophe Battail,
  • Claude Cochet,
  • Thierry Lomberget,
  • Odile Filhol,
  • Isabelle Krimm

Journal volume & issue
Vol. 27, no. 2
p. 108903

Abstract

Read online

Summary: Although the involvement of protein kinase CK2 in cancer is well-documented, there is a need for selective CK2 inhibitors suitable for investigating CK2 specific roles in cancer-related biological pathways and further exploring its therapeutic potential. Here, we report the discovery of AB668, an outstanding selective inhibitor that binds CK2 through a bivalent mode, interacting both at the ATP site and an allosteric αD pocket unique to CK2. Using caspase activation assay, live-cell imaging, and transcriptomic analysis, we have compared the effects of this bivalent inhibitor to representative ATP-competitive inhibitors, CX-4945, and SGC-CK2-1. Our results show that in contrast to CX-4945 or SGC-CK2-1, AB668, by targeting the CK2 αD pocket, has a distinct mechanism of action regarding its anti-cancer activity, inducing apoptotic cell death in several cancer cell lines and stimulating distinct biological pathways in renal cell carcinoma.

Keywords